Skip to main content

Vegzelma News

Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer

MONDAY, May 12, 2025 – The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according...

New Hope Against a Rare, Aggressive Form of Thyroid Cancer

MONDAY, Oct. 28, 2024 – Most thyroid cancers are slow-moving and, if caught early, curable. But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) – a rare and...

FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Colorectal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma

Vegzelma patient information at Drugs.com